• Quintino Giorgio D'Alessandris, Nicola Montano, Maurizio Martini, Tonia Cenci, Liverana Lauretti, Vittorio Stumpo, Fabrizio Pignotti, Alessandro Olivi, Eduardo Fernandez, Luigi Maria Larocca, and Roberto Pallini.
• Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy. giorgiodal@hotmail.it.
• Acta Neurochir (Wien). 2018 Dec 1; 160 (12): 2387-2391.

AbstractTreatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor-namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA-and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

33 keywords...

hide…